For research use only. Not for use in humans.

Bimagrumab (Anti-ACVR2B)

Synonyms: ACTR-IIB, Activin receptor type-2B

Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD.

Bimagrumab (Anti-ACVR2B)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Mechanism of Action

Description
Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD.

Product Details

CAS No. 1356922-05-8
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05933499 RECRUITING Drug: Bimagrumab|Drug: Tirzepatide Obesity Massachusetts General Hospital 2025-11-05 PHASE2
NCT06643728 ACTIVE_NOT_RECRUITING Drug: Bimagrumab|Drug: Tirzepatide|Drug: Bimagrumab Placebo| Obesity; Overweight Eli Lilly and Company 2024-10-21 PHASE2
NCT06890611 COMPLETED Drug: Bimagrumab|Drug: Tirzepatide|Drug: Bimagrumab + Tirzep Healthy Eli Lilly and Company 2025-03-25 PHASE1
NCT06901349 WITHDRAWN Drug: Bimagrumab|Drug: Tirzepatide|Drug: Bimagrumab Placebo| Obesity; Overweight Eli Lilly and Company 2025-05-23 PHASE2
NCT05616013 COMPLETED Drug: Semaglutide Obesity; Obese; Overweight or Obesity Eli Lilly and Company 2022-11-16 PHASE2
NCT03005288 COMPLETED Drug: BYM338 10 mg/kg Diabetes Mellitus, Type 2 Novartis Pharmaceuticals 2017-02-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-03-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.